China's CNBG Has Supplied 3 Million COVID-19 Vaccine Doses to UAE
The United
Arab Emirates (UAE) has received a total of three million COVID-19 vaccine
doses from China National Biotec Group (CNBG), the company said on Tuesday.
CNBG has
moved into late-stage clinical trials two COVID-19 vaccine candidates
respectively developed by its units in Beijing and Wuhan city. The Beijing
unit's shot obtained a green light last week for general public use in China.
CNBG is a
subsidiary of state-backed China National Pharmaceutical Group (Sinopharm).
"According
to preliminary feedback from UAE, emergency use shows that Sinopharm CNBG's
COVID-19 vaccine is safe in large-scale use and has significantly reduced the
disease in vaccinated people," CNBG said in an article published on
Chinese social media WeChat, without specifying which candidate it referred to.
The firm
didn't break down the numbers of doses for each candidate in its supply to UAE.
It's not immediately clear how many of these doses were used in clinical trials
and how many in real-life use.
